News

Video

Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study

Author(s):

David Miller, MD

David Miller, MD, reviews a plenary presentation (originally presented at the ASCO 2024 Annual Meeting by Vikky Makker, MD) on the long-term follow-up of the ENGOT-EN5/GOG-3055/SIENDO trial, focusing on selinexor maintenance for patients with TP53 wild-type advanced or recurrent endometrial cancer.

Related Videos
Matthew Powell, MD
Laura J. Chambers, DO
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study
Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial
Results From the Phase 1 Study of the Novel BCL2 Inhibitor Sonrotoclax in Combination with Zanubrutinib for Relapsed/Refractory CLL/SLL Show Deep and Durable Responses
Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Maurie Markman, MD
Related Content
Alexandra Leary, MD, PhD
September 12th 2024

Ibrilatazar Plus Chemotherapy Elicits Promising Activity in Recurrent Endometrial Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Maurie Markman, MD
August 30th 2024

Is the Current Framework of Academic Oncology Failing Community Providers?

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Ritu Salani, MD, director, Gynecologic Oncology, University of California Los Angeles
August 28th 2024

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer

Bhavana Pothuri, MD
August 26th 2024

Treatment Advances Underscore Need for MMR/MSI Testing in Advanced Endometrial Cancer